Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

Core Viewpoint - The company Inventiva has approved a share repurchase program aimed at enhancing market liquidity, with a maximum purchase limit of 10% of its capital over the next 18 months [1][4]. Group 1: Share Repurchase Program - The share repurchase program was approved during the Ordinary General Meeting on May 22, 2025, with the primary objective of animating the market under a liquidity agreement [1][2]. - The maximum number of shares that can be acquired is 13,869,673, considering the 45,454 shares already held in treasury as of May 19, 2025 [4]. - The maximum price per share for the repurchase is set at 40 euros [4]. Group 2: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH and other diseases with significant unmet medical needs [2]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the pivotal Phase 3 clinical trial for treating adult patients with MASH [2]. Group 3: Market Information - Inventiva is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States [3]. - The company has a total of 13,915,127 shares in its capital structure as of May 19, 2025 [4].